USPTO Invalidates Pharmacyclics Patent Challenged by BeiGene in BRUKINSA Dispute In a significant development in the ongoing intellectual property battle between two major players in the oncology therapeutics market, BeiGene,…
Xencor Reports Positive Interim Data From First-in-Human Study of XmAb942, Plans Phase 2b Trial for Inflammatory Bowel Disease Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company specializing in the development…
QIAGEN Expands Digital PCR Portfolio With Advanced Lentivirus Solutions to Elevate Quality Control in Cell and Gene Therapy Manufacturing QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA), a global leader in…
DEFINE-HT Clinical Trial Shows Prospera™ Heart Accurately Predicts Outcomes and Outperforms Biopsy in Heart Transplant Surveillance Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing,…
Guardant Health Unveils Compelling Data on Shield Multi-Cancer Detection Test at AACR 2025, Showcasing High Specificity and Sensitivity Across Ten Tumor Types Guardant Health, Inc. (Nasdaq: GH), a prominent leader…
Microba Life Sciences Achieves Breakthrough in IBD Diagnostics and Forms Strategic Partnership with Leading Gastroenterology Provider Microba Life Sciences Limited (ASX: MAP), a precision microbiome company at the forefront of…
D3 Bio Showcases Next-Generation KRAS G12C Inhibitor D3S-001 in Nature Medicine and AACR 2025 Presentation, Demonstrating Breakthrough Efficacy and Resistance Overcoming Potential D3 Bio, a clinical-stage biotechnology company at the…
InVitria Launches Optibumin® 25: A Groundbreaking 25% Recombinant Human Serum Albumin Designed for Closed-System Biomanufacturing InVitria, a recognized innovator in the development of recombinant, chemically defined components for biomanufacturing, has…
Shearwater Health Earns Great Place to Work® Certification Across U.S., Philippines, and India, Showcasing a Unified Commitment to Employee Well-Being Shearwater Health, a global leader in clinician-led clinical solutions, has…
Edgewood Oncology Unveils Compelling Preclinical Data Supporting BTX-A51 in Liposarcoma at AACR Annual Meeting 2025 Edgewood Oncology, a clinical-stage biotechnology company dedicated to advancing targeted cancer therapies, today announced new…
Mythic Therapeutics Presents Promising Preclinical Data Demonstrating Broad Antitumor Efficacy of MYTX-011 at the 2025 AACR Annual Meeting Mythic Therapeutics, a clinical-stage biotechnology company pioneering the next generation of antibody-drug…
Puma Biotechnology Showcases Promising Neratinib Combination Data at AACR Annual Meeting 2025 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company specializing in the development of innovative cancer treatments, has presented…